{"nct_id":"NCT03837509","title":"INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","status_verified_date":"2023-02","start_date":"2019-09-25","start_date_type":"ACTUAL","primary_completion_date":"2022-04-05","primary_completion_date_type":"ACTUAL","completion_date":"2022-04-05","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["INCY"]}